AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis
| Autor: | Giancarlo M. Liumbruno, Paolo Caraceni, Daniele Prati, Carlo Alessandria, Pierluigi Piccoli, Oliviero Riggio, Francesco Fiorin, Claudio Velati, Mauro Bernardi, Giuseppina Facco, Francesco Bennardello, Pierluigi Berti, Francesco Salerno, Paolo Angeli |
|---|---|
| Přispěvatelé: | Caraceni, P, Angeli, P, Prati, D, Bernardi, M, Liumbruno, Gm, Bennardello, F, Piccoli, P, Velati, C, Alessandria, C, Riggio, O, Salerno, F, Berti, P, Facco, G, Fiorin, F |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Models
Molecular Liver Cirrhosis Cirrhosis Hypovolemia 0302 clinical medicine Hepatorenal syndrome Models Ascites Paracentesis Immunology and Allergy Post-paracentesis circulatory dysfunction Evidence-Based Medicine medicine.diagnostic_test Gastroenterology Shock Hematology Acute Kidney Injury Liver Italy 030220 oncology & carcinogenesis Human albumin Ascite 030211 gastroenterology & hepatology medicine.symptom Hyponatremia medicine.medical_specialty Hepatorenal Syndrome Spontaneous bacterial peritoniti Peritonitis 03 medical and health sciences Spontaneous bacterial peritonitis Internal medicine Albumins medicine Humans Medical prescription Intensive care medicine Serum Albumin Hepatic Encephalopathy Hepatology business.industry Molecular Recommendation medicine.disease Clinical trial business |
| Popis: | The use of human albumin is common in hepatology since international scientific societies support its administration to treat or prevent severe complications of cirrhosis, such as the prevention of post-paracentesis circulatory dysfunction after large-volume paracentesis and renal failure induced by spontaneous bacterial peritonitis, and the treatment of hepatorenal syndrome in association with vasoconstrictors. However, these indications are often disregarded, mainly because the high cost of human albumin leads health authorities and hospital administrations to restrict its use. On the other hand, physicians often prescribe human albumin in patients with advanced cirrhosis for indications that are not supported by solid scientific evidence and/or are still under investigation in clinical trials. In order to implement appropriate prescription of human albumin and to avoid its futile use, the Italian Association for the Study of the Liver (AISF) and the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) nominated a panel of experts, who reviewed the available clinical literature and produced practical clinical recommendations for the use of human albumin in patients with cirrhosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|